Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

With the development of the blood coagulation industry, more and more IVD companies have joined it and actively expanded the related services.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China. Latest news

MVZ HPH Institute for Pathology and Hematopathology GmbH, today announced the availability of HPH MRD, a new tumor-informed circulating-tumor DNA (ctDNA) blood test for detecting minimal residual disease (MRD) in patients diagnosed with solid tumor cancers. The HPH MRD test is an in-house test manufactured by HPH that makes use of Haystack MRD technology and is available through a license from Haystack Oncology, a subsidiary of Quest Diagnostics® (NYSE: DGX), which developed and provides the Haystack MRD in-house developed test in the United States. The technology was purpose-built to detect ultralow levels of ctDNA with exceptional sensitivity and specificity, enabling the reliable identification of residual or recurrent disease.

Illumina, Inc. (NASDAQ: ILMN) today announced that GeneDx, a leader in genetic testing for rare diseases, is piloting Illumina's emerging constellation mapped read technology, evaluating its performance on regions of the genome that traditional short-read technologies historically have not resolved. GeneDx's early results illustrate the ability of constellation to rapidly identify hard-to-detect variants implicated in rare disease. GeneDx's Director of Laboratory Innovation Joe Devaney will present on the company's early experiences with the constellation technology today at the American Society for Human Genetics (ASHG) Annual Meeting in Boston.

In preliminary results reported on Wednesday after the close of the market, Becton Dickinson said its revenues in the fiscal fourth quarter of 2025 increased 8 percent year over year. The firm also announced the upcoming departure of its CFO and disclosed a transition plan for the position.

Samsung C&T (SCT), Samsung Electronics (SEC), and GRAIL, Inc. (Nasdaq: GRAL), today announced they have signed a binding Letter of Intent for a strategic collaboration to bring GRAIL's GalleriⓇ multi-cancer early detection (MCED) test to key Asian markets. SCT and SEC have also agreed to invest $110 million into GRAIL, a healthcare company whose mission is to detect cancer early when it can be cured, at a price of $70.05 per share of common stock.

Thermo Fisher Scientific, the world leader in serving science, has introduced the Applied Biosystems™ SwiftArrayStudio™ Microarray Analyzer, designed for fast and scalable sample analysis. In conjunction with two new arrays – the Applied Biosystems Axiom™ PharmacoPro™ Array and the Applied Biosystems Axiom PangenomePro Array – the analyzer combines four key genotyping processes into a single, integrated device, enabling researchers to cover the widest range of populations for Genome-Wide Association Studies (GWAS) and accelerate breakthrough discoveries in pharmacogenomics that will help drive the future of precision medicine forward.

Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2025.

OSR Holdings, Inc. (NASDAQ: OSRH) today announced that it has executed a definitive agreement to acquire Woori IO Co., Ltd. ("WORIO"), a pioneer in noninvasive glucose monitoring (NIGM), via a comprehensive share exchange. The acquisition reinforces OSRH's dedication to advancing biomedical innovation by adding a potential breakthrough technology for diabetes care, bringing truly needle-free glucose monitoring closer to patients globally and promising a safer, more convenient and accurate alternative to currently available technologies.

China leads the world in AI research publications related to the global medical device field over the past five years, according to a latest industrial white paper.

China’s National Health Commission (NHC) recently responded to a deputies’ proposal on “Lifting Restrictions on Diagnostic Testing Services in Clinics to Promote the Implementation of Tiered Healthcare”: